MannKind reported 201.15 in PE Price to Earnings for its fiscal quarter ending in March of 2026.





Pe Change Date
Adma Biologics 12.28 2.74 Jun/2026
BioCryst Pharmaceuticals 6.84 0.78 Jun/2026
Eli Lilly 64.5 31.61 Sep/2026
Halozyme Therapeutics 16.12 3.61 Sep/2026
MannKind 201.15 102.55 Mar/2026
Merck 34.36 2.11 Sep/2026
Novavax 2.01 1.07 Dec/2025
Novo Nordisk 9.94 0.47 Jun/2026
Pfizer 15.2 3.72 Sep/2026
Sanofi 22.34 3.38 Sep/2026
Xencor 29.92 3.22 Sep/2022